Novavax Executive and Leadership Team

John Jacobs, the President, Chief Executive Officer & Member of The Board of Directors at Novavax, directs the overarching corporate strategy and long-term vision for the biotechnology firm. Jacobs manages the integration of recombinant protein and nanoparticle technology to ensure the successful commercialization of vaccine candidates targeting COVID-19 and influenza. By fostering strategic partnerships with global pharmaceutical entities like Sanofi, the President, Chief Executive Officer & Member of The Board of Directors aligns internal research capabilities with international market demands. This leadership role involves constant engagement with the Board to optimize capital allocation and drive sustainable growth across North American and European markets. John Jacobs maintains a focus on operational excellence, ensuring that the company remains at the forefront of infectious disease prevention. Through rigorous oversight of organizational performance, Jacobs secures the necessary resources to advance the complex vaccine pipeline.

Louis Fries, the Chief Medical Officer at Novavax, oversees the scientific integrity and medical strategy for all vaccine development programs. Fries directs the evaluation of clinical data to ensure that proprietary adjuvant platforms meet stringent safety and efficacy standards for respiratory syncytial virus and other pathogens. The Chief Medical Officer coordinates with regulatory bodies to facilitate the approval of new medical interventions, bridging the gap between laboratory research and patient application. By analyzing complex immunological responses, Fries informs the strategic direction of the company's oncology and infectious disease initiatives. Louis Fries maintains a critical focus on medical governance, ensuring that every clinical trial adheres to global health protocols. This leadership position requires constant collaboration with internal research teams to refine the nanoparticle technology approach, ultimately strengthening the company's position as a leader in biotechnology innovation.

Mark Casey, the Executive Vice President & Chief Legal Officer at Novavax, manages the complex legal framework surrounding intellectual property, licensing agreements, and global corporate compliance. Casey directs the negotiation of strategic partnerships with major pharmaceutical companies, ensuring that all collaborative efforts align with the company's proprietary technology interests. The Executive Vice President & Chief Legal Officer mitigates operational risks by overseeing regulatory filings and protecting the company's patent portfolio across international jurisdictions. By providing legal counsel to the executive team, Casey supports the expansion of the vaccine pipeline into new therapeutic areas like malaria and shingles. Mark Casey maintains a focus on corporate governance, ensuring that all business activities comply with NASDAQ requirements and international trade laws. This role involves navigating intricate legal landscapes to facilitate the seamless commercialization of life-saving medical products on a global scale.

Raburn Mallory, the Senior Vice President, Head of Clinical Development and Deputy Chief Medical Officer at Novavax, executes the operational strategy for all phase-based clinical trials. Mallory directs the design and implementation of study protocols to validate the efficacy of recombinant protein vaccines against diverse infectious pathogens. The Senior Vice President, Head of Clinical Development and Deputy Chief Medical Officer manages cross-functional teams to accelerate the transition of candidates from early-stage research to late-stage clinical validation. By overseeing global trial sites, Mallory ensures that data collection meets the highest standards for regulatory submission. Raburn Mallory maintains a focus on optimizing clinical workflows, reducing time-to-market for critical vaccine solutions. This leadership role involves constant coordination with the Chief Medical Officer to align clinical milestones with the broader corporate mission of protecting public health through advanced biotechnology.